David Baker
Chairman chez DEVONIAN HEALTH GROUP INC.
Fortune : 32 $ au 31/03/2024
Profil
David C.
Baker was the founder of Vallon Pharmaceuticals, Inc. (founded in 2018) and held the title of Director.
He is currently the Chairman at Philadelphia Education Fund and the Non-Executive Chairman at Devonian Health Group, Inc. He also serves as a Director at Benchworks, Inc. and GRI Bio, Inc. Mr. Baker previously worked as the President & Chief Executive Officer at Alcobra Ltd.
from 2014 to 2017 and as the Vice President-Commercial Strategy & New Business at Shire Pharmaceuticals, Inc. from 2004 to 2013.
He completed his undergraduate degree at Duke University and holds an MBA from The Fuqua School of Business.
Détentions connues dans des sociétés publiques
Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
---|---|---|---|---|
GRI BIO, INC.
0,00% | 31/12/2023 | 42 ( 0,00% ) | 32 $ | 31/03/2024 |
01/12/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Postes actifs de David Baker
Sociétés | Poste | Début |
---|---|---|
GRI BIO, INC. | Director/Board Member | - |
DEVONIAN HEALTH GROUP INC. | Chairman | 04/12/2023 |
Philadelphia Education Fund | Chairman | - |
Benchworks, Inc.
Benchworks, Inc. Miscellaneous Commercial ServicesCommercial Services Benchworks, Inc. engages in the provision of marketing services. It offers brand development and strategy, creative services, print media and non personal promotion, and event planning and management. The company was founded by Thad L. Bench in 1991 and is headquartered in Chestertown, MD. | Director/Board Member | - |
Anciens postes connus de David Baker
Sociétés | Poste | Fin |
---|---|---|
GRI BIOPAR | Chief Executive Officer | 21/04/2023 |
Alcobra Ltd.
Alcobra Ltd. Pharmaceuticals: MajorHealth Technology Alcobra Ltd. engages in the research, development, and market of pharmaceutical productsfor the treatment of central nervous system disorders and cognitive dysfunctions. Its portfolio includes Metadoxine Extended Release to treat Attention Deficit Hyperactivity Disorder and Fragile X Syndrome. The company was founded by Ehud Moshe Gilboa and Dalia Megiddo on February 7, 2008 and is headquartered in Tel Aviv, Israel. | Chief Executive Officer | 01/11/2017 |
Shire Pharmaceuticals, Inc.
Shire Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Shire Pharmaceuticals, Inc. manufactures pharmaceutical products. The company offers solutions for attention deficit & hyperactivity disorder, human genetic therapies, gastrointestinal, and renal diseases. The company was founded in 1986 and is headquartered in Wayne, PA | Corporate Officer/Principal | 01/12/2013 |
Formation de David Baker
Duke University | Undergraduate Degree |
The Fuqua School of Business | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 1 |
---|---|
DEVONIAN HEALTH GROUP INC. | Health Technology |
Entreprise privées | 6 |
---|---|
Alcobra Ltd.
Alcobra Ltd. Pharmaceuticals: MajorHealth Technology Alcobra Ltd. engages in the research, development, and market of pharmaceutical productsfor the treatment of central nervous system disorders and cognitive dysfunctions. Its portfolio includes Metadoxine Extended Release to treat Attention Deficit Hyperactivity Disorder and Fragile X Syndrome. The company was founded by Ehud Moshe Gilboa and Dalia Megiddo on February 7, 2008 and is headquartered in Tel Aviv, Israel. | Health Technology |
Shire Pharmaceuticals, Inc.
Shire Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Shire Pharmaceuticals, Inc. manufactures pharmaceutical products. The company offers solutions for attention deficit & hyperactivity disorder, human genetic therapies, gastrointestinal, and renal diseases. The company was founded in 1986 and is headquartered in Wayne, PA | Health Technology |
Philadelphia Education Fund | |
Benchworks, Inc.
Benchworks, Inc. Miscellaneous Commercial ServicesCommercial Services Benchworks, Inc. engages in the provision of marketing services. It offers brand development and strategy, creative services, print media and non personal promotion, and event planning and management. The company was founded by Thad L. Bench in 1991 and is headquartered in Chestertown, MD. | Commercial Services |
Vallon Pharmaceuticals, Inc.
Vallon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Vallon Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It focuses on the development and commercialization of proprietary biopharmaceutical products. The firm's primary product is Abuse-Deterrent Amphetamine Immediate and its product pipeline includes ADAIR, ADMIR, ADHD, and Narcolepsy. The company was founded by David C. Baker on January 11, 2018 and is headquartered in Philadelphia, PA. | Health Technology |
GRI Bio, Inc. |